Nearly one-third of patients with coronavirus disease 2019 (COVID-19) have at least 1 dermatologic manifestation, with palmar erythema and scalp erythema most associated with hospitalization.

The investigators used an electronic survey to evaluate the prevalence of dermatologic manifestations in patients with COVID-19. Participants were recruited from 66,667 registered cell phone users in Brazil randomly assigned from a database; they were asked to complete the survey and to share it with their personal contacts.

The questionnaire addressed baseline demographics and COVID-19 status (never, suspected, or confirmed). For participants who had suspected or confirmed COVID-19, the survey included clinical outcomes and images of mucocutaneous manifestations. Dermatologic findings were assessed according to disease severity (outpatient vs hospitalized) and main demographic data. The analysis involved only self-reported confirmed cases (by polymerase chain reaction or serology) of COVID-19.

A total of 43,444 participants were included: 39,693 healthy participants, 2322 who were suspected or awaiting confirmation of COVID-19, and 1429 confirmed patients with COVID-19. Male sex (odds ratio [OR], 2.1), age older than 60 years (OR, 3.3), obesity (OR, 1.9), arterial hypertension (OR, 1.8), and diabetes (OR, 2.4) were independently associated with hospitalization (P <.05).In addition, 31% (95% CI, 28-33) of patients with COVID-19 had at least 1 dermatologic manifestation. Palmar erythema (OR, 3.6) and scalp erythema (OR, 2.1) were most associated with hospitalization. Papulovesicles were more common in patients younger than 30 years, pseudo-chilblains were more frequent in older adults, and scalp scaling and erythema were more common among nonwhite participants.

To know more about dermatology facts, kindly go through this journal homepage link: https://www.longdom.org/clinical-experimental-dermatology-research.html

Regards

Kathy Andrews
Managing Editor
Journal of Clinical & Experimental Dermatology Research